Charles River Laboratories International, Inc. filed a Form 8-K on November 9, 2026, disclosing that it has entered into definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations located in Exton, Pennsylvania.

Key Highlights

  • Definitive agreements signed: Charles River has entered into definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations, according to the filing.
  • Location of target operations: The operations being acquired are based in Exton, Pennsylvania, as disclosed in the filing.
  • Disclosure mechanism: The announcement was made via a press release issued on November 9, 2026, furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.
  • Forward-looking statements present: The attached press release includes "safe harbor" language under the Private Securities Litigation Reform Act of 1995, indicating certain statements are "forward-looking" rather than historic.
  • Signing authority: The filing was signed by Kerry Dailey, Corporate Senior Vice President and Chief Legal Officer of Charles River Laboratories International, Inc.

Charles River Discloses Frontage Holdings Bioanalysis and DMPK Acquisition Agreement

Charles River Laboratories International, Inc. (NYSE:CRL) filed a current report on November 9, 2026, under Item 7.01 Regulation FD Disclosure, announcing that the company "has entered into definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania," according to the filing. The announcement was communicated through a press release dated November 9, 2026, which was furnished as Exhibit 99.1 and incorporated by reference into the report.

The filing notes that the information disclosed under Item 7.01, including the accompanying exhibit, is furnished rather than filed, and therefore "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended." The press release referenced in the filing contains "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, which characterizes certain statements as "forward-looking" rather than historic. The filing further states that risks relating to Charles River "are set forth in the documents filed by Charles River with the Securities and Exchange Commission," per the company's own language in the press release.

No financial terms of the acquisition were included in the body of this Form 8-K filing. The report was signed by Kerry Dailey, Corporate Senior Vice President and Chief Legal Officer, on behalf of Charles River Laboratories International, Inc., a Delaware-incorporated company headquartered at 251 Ballardvale Street, Wilmington, Massachusetts 01887.

What Was Disclosed

Charles River Laboratories International, Inc. disclosed via an 8-K filed November 9, 2026, that it has signed definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania, with details provided in a furnished press release.